Ekso Bionics Reports Record Revenues of $4.7 Million in Second Quarter 2023
Record number of EksoHealth devices booked in second quarter 2023
SAN RAFAEL, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2023.
Recent Highlights and Accomplishments
- Achieved record revenues of $4.7 million in the second quarter of 2023, an increase of 36% year-over-year
- Booked a total of 44 EksoHealth devices in the second quarter of 2023
- Gross profit of $2.3 million in the second quarter of 2023, compared to $1.6 million in the same period last year
- Cash position of $13.3 million as of June 30, 2023
“Our strong second quarter results reflect solid commercial execution and continued growth in bookings from our clinical and personal use device customers,” said Scott Davis, Chief Executive Officer of Ekso Bionics. “Highlighted by a record number of EksoHealth device bookings resulting in robust revenue growth of 36% year-over-year, more patients than ever are benefitting from our innovative portfolio of exoskeleton devices across the continuum of care. Looking ahead, we remain focused on securing more multi-unit orders with large network operators to drive sustainable, long-term growth.”
Second Quarter 2023 Financial Results
Revenue was $4.7 million for the quarter ended June 30, 2023, an increase of 36%, compared to $3.5 million for the same period in 2022. The Company booked a total of 44 EksoHealth devices in the second quarter of 2023.
Gross profit for the quarter ended June 30, 2023 was $2.3 million, an increase of 37% from the same period in 2022, representing a gross margin of approximately 48% in the second quarter of 2023, compared to a gross margin of 47% for the same period in 2022. The increase in gross margin was primarily due to lower device costs.
Sales and marketing expenses for the quarter ended June 30, 2023 were $2.3 million, compared to $1.8 million for the same period of 2022. The increase was primarily due to higher compensation costs associated with the acquisition of the Human Motion Control (“HMC”) business unit, severance expense and an increase in marketing activities.
Research and development expenses for the quarter ended June 30, 2023 were $1.4 million, compared to $0.9 million for the same period of 2022. The increase was primarily due to higher costs associated with the acquisition of HMC.
General and administrative expenses for the quarter ended June 30, 2023 were $2.8 million, compared to $2.2 million for the same period in 2022. The increase was primarily due to HMC-related audit and integration costs.
Net loss applicable to common stockholders for the quarter ended June 30, 2023 was $4.2 million, or $0.31 per basic and diluted share, compared to net loss of $3.0 million, or $0.23 per basic and diluted share, for the same period in 2022.
Six Months Ended June 30, 2023
Revenue was $8.8 million for the six months ended June 30, 2023, an increase of 46%, compared to $6.0 million for the same period in 2022. The Company booked a total of 67 EksoHealth devices in the first half of 2023.
Gross profit for the six months ended June 30, 2023 was $4.3 million, representing a gross margin of approximately 48%, compared to gross profit of $2.9 million for the same period in 2022, representing a gross margin of 47%. The overall increase in gross margin was primarily due to lower device costs.
Sales and marketing expenses for the six months ended June 30, 2023 were $4.4 million, compared to $3.5 million the same period in 2022. The increase was primarily due to higher compensation costs associated with the acquisition of HMC, an increase in marketing activities, and severance expense.
Research and development expenses for the six months ended June 30, 2023 were $2.6 million, compared to $1.8 million for the same period in 2022. The increase was primarily due to higher costs associated with the acquisition of HMC.
General and administrative expenses for the six months ended June 30, 2023 were $6.0 million, compared to $5.1 million for the same period in 2022. The increase was primarily due to HMC-related audit and integration costs.
Net loss applicable to common stockholders for the six months ended June 30, 2023 was $8.6 million, or $0.64 per basic and diluted share, compared to net loss of $7.6 million, or $0.59 per basic and diluted share, for the same period in 2022.
Cash on hand on June 30, 2023 was $13.3 million, compared to $20.5 million at December 31, 2022.
Conference Call
Management will host a conference call today beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the Company’s financial results and recent business developments.
A live webcast of the event is available in the “Investors” section of the Company’s website at www.eksobionics.com, or by clicking here. Investors interested in listening to the conference call may do so by dialing 877-407-3036 for domestic callers or 201-378-4919 for international callers. The webcast will also be available on the Company’s website for one month following the completion of the call.
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance, and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: www.eksobionics.com or follow @EksoBionics on Twitter.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding the plans, objectives and expectations of management with respect to the Company’s industry, growth and strategy, including the Company’s focus on securing more multi-unit orders with large network operators and its ability to obtain sustainable, long-term growth, the expected benefits of the acquisition of HMC, potential technological and operational improvements and the assumptions underlying or relating to the foregoing. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund and grow the Company's operations and necessary to develop or enhance the Company’s technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of the Company’s sales and marketing efforts or of partners to market the Company’s products effectively, adverse results in future clinical studies of the Company's medical device products, the failure of the Company to obtain or maintain patent protection for the Company's technology, the failure of the Company to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, disruptions in the Company’s supply chain, the Company’s ability to successfully integrate the HMC business and its personnel, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company’s most recently filed Annual Report on Form 10-K and its subsequently filed Quarterly Reports on Form 10-Q. To learn more about Ekso Bionics please visit the Company’s website at www.eksobionics.com or refer to the Company’s Twitter page at @EksoBionics. Any forward-looking statements made in this press release speak only as of the date of this press release. The Company does not undertake to update these forward-looking statements, except as required by law.
Contact:
David Carey
212-867-1768
investors@eksobionics.com
| Ekso Bionics Holdings, Inc. | |||||||
| Condensed Consolidated Balance Sheets | |||||||
| (In thousands) | |||||||
| June 30, | December 31, | ||||||
| 2023 | 2022 | ||||||
| (Unaudited) | |||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and restricted cash | $ | 13,307 | $ | 20,525 | |||
| Accounts receivable, net | 5,052 | 4,625 | |||||
| Inventories | 5,602 | 5,187 | |||||
| Prepaid expenses and other current assets | 759 | 700 | |||||
| Total current assets | 24,720 | 31,037 | |||||
| Property and equipment, net | 2,304 | 2,680 | |||||
| Right-of-use assets | 1,146 | 1,307 | |||||
| Intangible assets, net | 5,053 | 5,217 | |||||
| Goodwill | 431 | 431 | |||||
| Other assets | 332 | 231 | |||||
| Total assets | $ | 33,986 | $ | 40,903 | |||
| Liabilities and Stockholders' Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 3,155 | $ | 3,151 | |||
| Accrued liabilities | 2,393 | 2,278 | |||||
| Deferred revenues, current | 1,286 | 1,121 | |||||
| Notes payable, current | 2,937 | 2,310 | |||||
| Lease liabilities, current | 358 | 341 | |||||
| Total current liabilities | 10,129 | 9,201 | |||||
| Deferred revenues | 1,632 | 1,032 | |||||
| Notes payable, net | 3,301 | 3,767 | |||||
| Lease liabilities | 907 | 1,087 | |||||
| Warrant liabilities | 107 | 233 | |||||
| Other non-current liabilities | 103 | 141 | |||||
| Total liabilities | 16,179 | 15,461 | |||||
| Stockholders' equity: | |||||||
| Common stock | 14 | 13 | |||||
| Additional paid-in capital | 250,000 | 248,813 | |||||
| Accumulated other comprehensive income | 359 | 563 | |||||
| Accumulated deficit | (232,566 | ) | (223,947 | ) | |||
| Total stockholders' equity | 17,807 | 25,442 | |||||
| Total liabilities and stockholders' equity | $ | 33,986 | $ | 40,903 | |||
| Ekso Bionics Holdings, Inc. | ||||||||||||
| Condensed Consolidated Statements of Operations | ||||||||||||
| (In thousands, except per share amounts) | ||||||||||||
| (Unaudited) | ||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||
| Revenue | $ | 4,703 | $ | 3,465 | $ | 8,825 | $ | 6,032 | ||||
| Cost of revenue | 2,449 | 1,824 | 4,571 | 3,182 | ||||||||
| Gross profit | 2,254 | 1,641 | 4,254 | 2,850 | ||||||||
| Operating expenses: | ||||||||||||
| Sales and marketing | 2,349 | 1,841 | 4,437 | 3,470 | ||||||||
| Research and development | 1,398 | 873 | 2,552 | 1,793 | ||||||||
| General and administrative | 2,791 | 2,156 | 5,997 | 5,053 | ||||||||
| Total operating expenses | 6,538 | 4,870 | 12,986 | 10,316 | ||||||||
| Loss from operations | (4,284 | ) | (3,229 | ) | (8,732 | ) | (7,466 | ) | ||||
| Other (expense) income, net: | ||||||||||||
| Interest expense, net | (61 | ) | (29 | ) | (172 | ) | (56 | ) | ||||
| Gain on revaluation of warrant liabilities | 152 | 999 | 126 | 899 | ||||||||
| Unrealized (loss) gain on foreign exchange | (7 | ) | (718 | ) | 210 | (972 | ) | |||||
| Other expense, net | (30 | ) | (1 | ) | (51 | ) | (3 | ) | ||||
| Total other income (expense), net | 54 | 251 | 113 | (132 | ) | |||||||
| Net loss | $ | (4,230 | ) | $ | (2,978 | ) | $ | (8,619 | ) | $ | (7,598 | ) |
| Net loss per share, basic and diluted | $ | (0.31 | ) | $ | (0.23 | ) | $ | (0.64 | ) | $ | (0.59 | ) |
| Weighted average number of shares of common | ||||||||||||
| stock outstanding, basic and diluted | 13,637 | 12,884 | 13,467 | 12,807 | ||||||||
Released July 27, 2023